vs

Side-by-side financial comparison of Canaan Inc. (CAN) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.

Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $20.6M, roughly 1.0× Entrada Therapeutics, Inc.). Canaan Inc. runs the higher net margin — -18.4% vs -84.4%, a 66.0% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.

CAN vs TRDA — Head-to-Head

Bigger by revenue
CAN
CAN
1.0× larger
CAN
$20.8M
$20.6M
TRDA
Higher net margin
CAN
CAN
66.0% more per $
CAN
-18.4%
-84.4%
TRDA

Income Statement — Q3 FY2025 vs Q1 FY2025

Metric
CAN
CAN
TRDA
TRDA
Revenue
$20.8M
$20.6M
Net Profit
$-3.8M
$-17.3M
Gross Margin
99.9%
Operating Margin
-15.9%
-106.0%
Net Margin
-18.4%
-84.4%
Revenue YoY
-65.2%
Net Profit YoY
-173.8%
EPS (diluted)
$-0.05
$-0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
TRDA
TRDA
Q4 25
$20.8M
Q3 25
$13.8M
Q2 25
$11.4M
Q1 25
$20.6M
Q4 24
$37.4M
Q3 24
$10.2M
$19.6M
Q2 24
$4.8M
$94.7M
Q1 24
$59.1M
Net Profit
CAN
CAN
TRDA
TRDA
Q4 25
$-3.8M
Q3 25
$-1.5M
Q2 25
$-11.9M
Q1 25
$-17.3M
Q4 24
$1.1M
Q3 24
$-10.4M
$-14.0M
Q2 24
$-5.4M
$55.0M
Q1 24
$23.5M
Gross Margin
CAN
CAN
TRDA
TRDA
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q1 25
Q4 24
Q3 24
99.9%
Q2 24
99.8%
Q1 24
Operating Margin
CAN
CAN
TRDA
TRDA
Q4 25
-15.9%
Q3 25
-27.0%
Q2 25
-45.5%
Q1 25
-106.0%
Q4 24
-15.7%
Q3 24
-77.2%
-110.7%
Q2 24
-193.9%
56.4%
Q1 24
35.7%
Net Margin
CAN
CAN
TRDA
TRDA
Q4 25
-18.4%
Q3 25
-11.0%
Q2 25
-104.4%
Q1 25
-84.4%
Q4 24
3.0%
Q3 24
-102.7%
-71.7%
Q2 24
-112.3%
58.1%
Q1 24
39.7%
EPS (diluted)
CAN
CAN
TRDA
TRDA
Q4 25
$-0.05
Q3 25
$-0.02
Q2 25
$-0.25
Q1 25
$-0.42
Q4 24
$-0.20
Q3 24
$-0.35
Q2 24
$1.55
Q1 24
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
TRDA
TRDA
Cash + ST InvestmentsLiquidity on hand
$67.8M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$417.3M
Total Assets
$92.5M
$486.5M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
$67.8M
Q4 24
$101.2M
Q3 24
$78.0M
Q2 24
$185.3M
Q1 24
$68.4M
Total Debt
CAN
CAN
TRDA
TRDA
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CAN
CAN
TRDA
TRDA
Q4 25
$52.4M
Q3 25
$44.7M
Q2 25
$33.8M
Q1 25
$417.3M
Q4 24
$428.7M
Q3 24
$43.6M
$422.4M
Q2 24
$56.8M
$429.9M
Q1 24
$269.4M
Total Assets
CAN
CAN
TRDA
TRDA
Q4 25
$92.5M
Q3 25
$81.7M
Q2 25
$78.0M
Q1 25
$486.5M
Q4 24
$526.3M
Q3 24
$69.3M
$554.6M
Q2 24
$73.7M
$582.0M
Q1 24
$510.8M
Debt / Equity
CAN
CAN
TRDA
TRDA
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
TRDA
TRDA
Operating Cash FlowLast quarter
$-38.5M
Free Cash FlowOCF − Capex
$-39.7M
FCF MarginFCF / Revenue
-192.9%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-58.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
$-38.5M
Q4 24
$-31.6M
Q3 24
$-24.3M
Q2 24
$39.8M
Q1 24
$-25.5M
Free Cash Flow
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
$-39.7M
Q4 24
$-32.2M
Q3 24
$-24.9M
Q2 24
$38.8M
Q1 24
$-26.4M
FCF Margin
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
-192.9%
Q4 24
-86.2%
Q3 24
-127.3%
Q2 24
41.0%
Q1 24
-44.6%
Capex Intensity
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
5.6%
Q4 24
1.7%
Q3 24
3.3%
Q2 24
1.1%
Q1 24
1.4%
Cash Conversion
CAN
CAN
TRDA
TRDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-27.94×
Q3 24
Q2 24
0.72×
Q1 24
-1.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons